Covaxin Shows High Efficacy Against Delta Plus Variant

Covaxin proves effective against the Delta Plus variant of COVID-19 with an overall efficacy of 77.8% against symptomatic infection in July.

Covaxin proves effective against Delta Plus variant of COVID-19 as per an ICMR (Indian Council of Medical Research) study.

Covaxin was approved for emergency use on January 3 2021 by India’s drugs regulator, Dr VG Somani. Now the vaccine has now received emergency use authorisations (EUAs) in 16 countries including, Brazil, India, Philippines, Iran, Mexico, with EUAs in process in 50 countries worldwide.

COVID-19 Vaccination in India: Issues and Challenges
India’s COVID-19 vaccination program has been launched. It currently uses the vaccines Covishield and Covaxin. There are some issues and challenges that need to be overcome in order to vaccinate all Indians.

‘Covaxin proves effective against the Delta Plus variant of COVID-19 as per an ICMR study. The vaccine demonstrated overall efficacy of 77.8% against symptomatic infection in July and now awaits WHO approval for emergency use listing (EUL). ’

The Delta Plus virus (also known as AY.1 variant) was first discovered in India and is a mutated form of the Delta variant (B.1.617.2 strain) of coronavirus. Around 70 cases of the Delta Plus variant were found by INSACOG (Indian SARS-CoV-2 Genomics Consortium), a group of 28 laboratories involved in genome sequencing, says Jitendra Singh, Union Science and Technology Minister in Parliament last week (in July).

Efficacy of Covaxin

Covaxin is the first indigenous vaccine of India to fight COVID-19, developed by Bharat Biotech, in collaboration with ICMR. So far, 430 million doses of vaccine have been distributed across India – one of the world's largest vaccination drives.

CoWIN Hits Vaccine Registration For 18+
In the third phase of vaccination drive, everyone above the age of 18 will be eligible to get vaccinated against Covid-19.

The first interim analysis by Bharat Biotech – the Hyderabad-based company, revealed almost 81% efficacy for Covaxin in March. The analysis included 43 cases, of which 36 cases of COVID-19 were observed in the placebo group versus 7 cases observed in the BBV152 (Covaxin) group.

The second interim analysis released April showed that the vaccine's efficacy against severe COVID-19 disease was 100%.

Alert: Beware of Fake 'CoWIN' Apps
In India, the Union Health Ministry has asked people not to download or register on several fraudulant applications named 'CoWIN' which are available on app-stores.

The vaccine demonstrated overall efficacy of 77.8% against symptomatic infection in July. The Company now affirms that it is in discussions with the World Health Organization (WHO) to obtain emergency use listing (EUL) for Covaxin.

Source-Medindia

Side Effects of Covid Vax Minuscule in India
Bleeding and clotting after taking the Covid-19 vaccination was found to be rare in India. Covishield continues to prevent infections and reduce deaths caused due to Covid pandemic across the world and in India.